PDCD1 and neoplasm: Since we observed that following vaccination there was an increased expression of PD-1 in tumor infiltrating CD8+ T cells, we sought to evaluate whether the efficacy of MS-OVA could be improved by combining with commercially available antibodies against PD-1 and other inhibitory receptors.